CYRX (Life Sciences Tools & Services) Stock Valuation & Fair Value Significantly overvalued
CYRX (Life Sciences Tools & Services) trades at a blended P/E of 109.7, about 1499% above its historical normal valuation, with a forward growth estimate of -105.1% and a PEG of —.
Valuation flags
- Overvalued by 1499%
- Negative growth forecast
Frequently asked questions
Is CYRX overvalued?
At a blended P/E of 109.7 versus its historical normal P/E of 6.9, CYRX trades about 1499% above its typical valuation. tickerseer currently rates it significantly overvalued.
What is CYRX's fair value and PEG?
CYRX trades at a blended P/E of 109.7 against a historical normal P/E of 6.9, and a forward growth estimate of -105.1%.
Has tickerseer's rating of CYRX changed?
tickerseer's rating has been significantly overvalued since 2026-07-31.
Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.